UKAR will be a collaborative epidemiological study through which BSAC partnerships with a UK university and industry partners. The Registry will initially be open for intravenous antibiotics, with a particular focus on multi-drug resistant organisms.
The registry will be overseen by an expert steering group to ensure appropriate consent and governance at all levels of implementation.
BSAC is now looking to engage a lead principal investigator to lead the study and also engage with a university partner who has experience of running other patient registries.
This will be a lean project with tight timescales but is an exciting opportunity to be part of a programme with national and international importance.
Please express interest to Tracey Guise, CEO,BSAC by July 10th 2020 by using the contact form available here.